Pancreatic carcinoma ranks as the eighth most frequent type of solid tumour
arising worldwide yet it represents the fourth most frequent cause of deat
h, This discrepancy reflects the current lack of effective treatment availa
ble for the pancreatic cancer patient and highlights the urgent need for ne
w therapeutic principles in this area,The last five years have seen an incr
easing number of novel approaches both in the pre-clinical area as well as
in clinical trials for pancreatic cancer treatments. This review summarizes
these new developments and attempts to rationalize the possibilities avail
able for the patient at the beginning of the new millennium.